natgillin/translations-raw huggingface dataset:
21 x 20 mg capsules (60 mg/day dose for a 7-day supply) Each 60 mg daily dose contains three grey 20 mg capsules.
21 kapsula od 20 mg (dnevna doza od 60 mg za primjenu tijekom 7 dana) Svaka dnevna doza od 60 mg sadrži tri sive kapsule od 20 mg.
21 x 20 mg capsules and 7 x 80 mg capsules (140 mg/day dose for a 7-day supply)
21 kapsula od 20 mg i 7 kapsula od 80 mg (dnevna doza od 140 mg za primjenu tijekom 7 dana).
21,924 (2-65 years)
21.924 (2-65 godina)
21-23 gauge needle(s) (recommended)
Igle od 21-23 G (preporučeno)
21-28 Days Post Booster
21-28 dana nakon boostera
21-gauge needle
21-G igla
21-March-2012
21. ožujka 2012.
21.1 months
21,1 mjeseca
21.1 months
21,1 mjeseci
21.3 to 23.1
21,3 do 23,1
21.4 mg/ml emodepside, 85.8 mg/ml praziquantel
21,4 mg/ml emodepsid, 85,8 mg/ml prazikvantel
21.4 months, HR = 0.84, 97.5% CI = [0.68; 1.04]; p-value = 0.0698.
21,4 mjeseca u bolesnika liječenih bevacizumabom, HR = 0,84; 97,5% CI = [0,68; 1,04]; p-vrijednost = 0,0698.
21.6 m vs 21.9 m
21,6 m vs 21,9 m
210 (3 x 70 x 1)
210 (3 x 70 x 1) kapsula (jedinična
210 (3 x 70 x 1) capsules (unit dose) (multipack)
210 (3 x 70 x 1) kapsula
210 (3 x 70 x 1) capsules (unit dose) (multipack)
210 (3 x 70 x 1) kapsula (jedinična
210 ml oral solution with a measuring spoon.
210 ml oralne otopine s mjernom žlicom.
2100 Gödöllö Hungary
2100 Gödöllö Mađarska
2100 Gödöllő Hungary
2100 Gödöllő Mađarska
2100 U of conestat alfa.
2100 U konestata alfa
2112 Veresegyhaz Hungary‌
2112 Veresegyhaz Mađarska
211]
106b
2132 JH Hoofddorp NETHERLANDS
2132 JH Hoofddorp NIZOZEMSKA
2132 JH Hoofddorp The Netherlands
2132 JH Hoofddorp Nizozemska
219 of the women had cancer that was expressing large quantities of HER2.
219 žena imale su karcinom s ekspresijom velikih količina HER2.
22 August 2014
22 kolovoz 2014
22 July 2016
22. srpnja 2016.
22 micrograms
/ 22 mikrograma
22 micrograms
22 mikrograma
22 micrograms (6 million IU)/0.5 mL
22 mikrograma (6 milijuna IU)/0,5 ml
22 micrograms [n=205] and placebo [n = 207], all administered once daily.
92 mikrograma [n=206], vilanterol od 22 mikrograma [n=205] i placebo [n = 207] (svi su se primjenjivali jedanput na dan).
22 micrograms tiw
22 mikrograma tri puta tjedno
22 mmol/L. The duration of low bicarbonate measurements was also long (median 188 days).
Niske razine bikarbonata u mjerenjima dugo su se održale (188 dana).
22 Seagoe Industrial Estate Craigavon BT63 5QD United Kingdom
22 Seagoe Industrial Estate Craigavon BT63 5QD Ujedinjena Kraljevina
22 Seagoe Industrial Estate Craigavon BT63 5QD United Kingdom
22 Seagoe Industrial Estate Craigavon BT63 5QD Ujedinjeno Kraljevstvo
22 to 143 ml/min) in the 64 patients studied.
29 ml/min (raspon od 22 do 143 ml/min) u 64 ispitivana bolesnika.
22 to < 24
22 do < 24
22.1 (17.1 to 24.0)
22,1 (17,1 do 24,0)
22.3 (20.3, NE)
22,3 (20,3; NO)
22.7 (18.0 to 34.0)
22,7 (18,0 do 34,0)
22.7 mg pyriproxifen, 1,865 mg permethrin
22.7 mg piriproksifena, 1865 mg permetrina
22.75m; 95%
95% CI:
22.8 (18.6, NR)
22,8 (18,6; ND)
22.8 months median observation time
medijan vremena promatranja: 22,8 mjeseci
22.9 % and 22.5 % of the patients had a CrCL > 50-< 80 mL/min, and 4.1 % and 4.8 % had a CrCL between 30 and 50 mL/min in in the RE-MEDY and RE-SONATE studies.
22,9 % i 22,5 % bolesnika imalo je CrCL > 50 -< 80 mL/min, a 4,1 % i 4,8 % imalo je CrCL između 30 i 50 mL/min u ispitivanjima RE-MEDY i RE-SONATE.
22.9 % and 22.5 % of the patients had a CrCL > 50-< 80 mL/min, and 4.1 % and 4.8 % had a CrCL between 30 and 50 mL/min in in the RE-MEDY and RE-SONATE studies.
22,9 % i 22,5 % bolesnika imalo je CrCL > 50-< 80 mL/min, a 4,1 % i 4,8 % imalo je CrCL između 30 i 50 mL/min u ispitivanjima RE-MEDY i RE-SONATE.
22005 data.
2Podaci iz 2005. g.
222 Regent Street, London, W1B 5TR United Kingdom
222 Regent Street, London, W1B 5TR Ujedinjena Kraljevina
222 x 106 cells/L for the rilpivirine and efavirenz treatment arms, respectively, of patients receiving the emtricitabine/tenofovir disoproxil fumarate background regimen.
+226 x 106 stanica/l u skupini liječenoj rilpivirinom i +222 x 106 stanica/l u skupini liječenoj efavirenzom.
224 (4 x 56) capsules and 5 inhalers (monthly multipack)
224 (4 x 56) kapsula i 5 inhalatora (mjesečno višestruko pakiranje)
224 (4 x 56) inhalation powder, hard capsules and 5 inhalers (monthly multipack)
224 (4 x 56) prašak inhalata, tvrde kapsule i 5 inhalatora (mjesečno višestruko pakiranje)
225 IU (450 IU/mL) recombinant follicle-stimulating hormone (FSH) activity.
225 IU (450 IU/ml) aktivnosti rekombinantnog folikulostimulirajućeg hormona (FSH).
225 mg capsules:
225 mg kapsule:
225 mg hard capsule
Pregabalin Mylan 225 mg tvrde kapsule
225 ml oral suspension
225 ml oralne suspenzije
23 July 2014
23. srpnja 2014.
23 kg up to 40 kg
23 kg do 40 kg
23 subjects experienced clinical worsening events in the placebo group (17.6 %) compared with 8 subjects in the sildenafil group (6.0 %).
U skupini koja je primala placebo epizode kliničkog pogoršanja doživjela su 23 ispitanika (17,6%), u usporedbi s 8 ispitanika u skupini liječenoj sildenafilom (6,0%).
23 ± 7.5 µg•h/mL, and 0.45 ± 0.26 µg/mL for elvitegravir, which provides inhibitory quotient of ~ 10 (ratio of Ctrough: protein binding-adjusted IC95 for wild-type HIV-1 virus).
1,7 ± 0,39 µg/ml, odnosno 23 ± 7,5 µg•h/ml, i 0,45 ± 0,26 µg/ml za elvitegravir, što omogućuje inhibitorski kvocijent od ~ 10 (omjer Ctrough: IC95 s prilagođenim proteinskim vezivanjem za divlji tip virusa HIV-1).
23-24 Tafarnaubach Industrial Estate, Tredegar,
23-24 Tafarnaubach Industrial Estate Tredegar,
23-valent pneumococcal polysaccharide vaccines in children ≥ 2 years of age with conditions (such as sickle cell disease, asplenia, HIV infection, chronic illness, or those who are immuno-compromised) placing them at higher risk for invasive disease due to Streptococcus pneumoniae.
23-valentnog pneumokoknog polisaharidnog cjepiva u djece u dobi od 2 ili više godina sa zdravstvenim tegobama (kao što je anemija srpastih stanica, asplenija, HIV-infekcija, kronična bolest ili imunokompromitiranost), zbog kojih su izložena većem riziku od invazivne bolesti izazvane bakterijom Streptococcus pneumoniae.
23.2 to 25.0
23,2 do 25,0
23.9% (17.6%; 30.3%)f
23,9% (17,6%; 30,3%)f
2300 Copenhagen S Denmark
2300 Copenhagen S Danska
2300 København S Denmark
Kay Fiskers Plads 11 2300 København S Danska
2333 BE Leiden The Netherlands
NL-2333 BE Leiden Nizozemska
2333 CR Leiden
2333 CR Leiden Niozemska
2333 CR Leiden Netherlands
2333 CR Leiden Nizozemska
2333 CR, Leiden The Netherlands
2333 CR, Leiden Nizozemska
2340 Beerse Belgium
2340 Beerse Belgija
237 Regents Park Road N3 3LF London UNITED KINGDOM
237 Regents Park Road N3 3LF London VELIKA BRITANIJA
23843 Bad Oldesloe Germany
23843 Bad Oldesloe Njemačka
24 alcohol swabs
24 jastučića natopljenih alkoholom
24 applicators
24 Aplikatora
24 Boulevard Vital Bouhot CS 50004
24, Boulevard Vital Bouhot CS 50004
24 capsules
24 kapsula
24 capsules
24 kapsule
24 film-coated tablets
24 filmom obloženih tableta
24 gastro-resistant tablets
24 želučanootporne tablete
24 hard capsules 48 hard capsules 60 hard capsules 96 hard capsules 120 hard capsules
24 tvrde kapsule 48 tvrdih kapsula 60 tvrdih kapsula 96 tvrdih kapsula 120 tvrdih kapsula
24 hard capsules 48 hard capsules 96 hard capsules 120 hard capsules
24 tvrdih kapsula 48 tvrdih kapsula 96 tvrdih kapsula 120 tvrdih kapsula
24 hour DBP at week 123
24-satni DKT u 12. tjednu3
24 Hour Mean SBP: LS Mean Change from Baseline (BL) to Week 6 (mm Hg)
24-satni prosječni sistolički krvni tlak: LS prosječna promjena od početne vrijednosti do 6. tjedna (mm Hg)
24 hours after a 220 mg dabigatran dose), was on average 22.0 ng/mL, with a range of 13.0-35.7 ng/mL (25th-75th percentile range).
24 sata nakon doze dabigatrana od 220 mg), bila je u prosjeku 22,0 ng/mL, s rasponom od 13,0-35,7 ng/mL (percentilni raspon 25.-75.).
24 hours at 2°C − 8°C protected from light.
2°C do 8°C zaštićen od svjetlosti.
24 hours to 48 hours after treatment initiation
24 do 48 sati nakon početka liječenja
24 hours with the exception of bilirubin (up to
24 sata uz iznimku bilirubina (do
24 hours, the plasma levels of sildenafil were still approximately 200 ng/ml, compared to approximately 5 ng/ml when sildenafil was administered alone.
Nakon 24 sata su plazmatske razine sildenafila još uvijek bile oko 200 ng/ml, u usporedbi s približno 5 ng/ml kada se sildenafil primjenjivao sam.
24 mg orally once daily
24 mg peroralno jedanput na dan
24 ml/hour (300 μg/min)
24 ml/sat (300 µg/min)
24 month
24 mjeseci
24 months 64.5% (58.3-70.3)
24 mjeseca
24 months after the 1st dose N=411
24 mjeseca nakon
24 months.
24 mjeseca
24 pre-filled syringes alcohol swabs
24 napunjene štrcaljke jastučića natopljena alkoholom
24 sachets
24 vrećice
24 spot-on applicators
24 aplikatora za nakapavanje
24 tablets
24 tableta
24 tablets
28 tablete
24 tablets (3 blister strips with 8 tablets each)
24 tablete (3 blister trake s 8 tableta)
24 tablets (4 blister strips with 6 tablets each)
24 tablete (4 blister trake s 6 tableta )
24 tablets (6 blister strips with 4 tablets each)
24 tablete (6 blister trake s 4 tablete)
24 to < 27
24 do < 27
24 to less than 36
24 do manje od 36
24 transdermal patches
24 transdermalnih flastera
24 units selected
24 jedinice
24 units selected
odabrane 24 jedinice
24 V4
24 V
24 vials of powder
24 bočice s praškom
24 Weeks
24. tjedan
24 weeks (n = 109)
24 tjedna (n = 109)
24 weeks (n = 114)
24 tjedna (n = 114)
24 weeks (n = 163)a
24 tjedna (n = 109)
24 weeks (n = 176)
24 tjedna (n = 176)
24 weeks (n = 243)
24 tjedna (n = 243)
24 weeks (n = 275)
24 tjedna (n = 275)
24 weeks (n = 28)
24 tjedna (n = 28)
24 weeks (n = 67)
24 tjedna (n = 67)
24 weeks (see section 5.1.)
24 tjedna (vidjeti dio 5.1.)
24 weeks or
24 tjedna ili
24 weeks TE (n = 13)
24 tjedna TE (n = 13)
24 weeks TE (n = 15)
24 tjedna TE (n = 15)
24 weeks treatment duration
24-tjedno liječenje
24 weeks ± SD
Početna prosječna vrijednost ± SD
24 weeks, or 12 infusions of ofatumumab only over 24 weeks.
12 infuzija ofatumumaba tijekom 24 tjedna.
24 weeks3
24 tjedna3
24 weeksa
24 tjednaa
24 x 1 tablets (unit
24 x 1 tablete (s jediničnim dozama)
24 – 120 hours
24 – 120 sati
24% [7/29], p=0.032).
24% [7/29], p=0,032).
24, 26 months
24, 26 mjeseci
24-120 hours
24 – 120 sati
24-35 months
12-23 mjeseci
24-35 months
24-35 mjeseci
24-month mechanistic study in male rats demonstrated that administration of pioglitazone resulted in an increased incidence of hyperplastic changes in the bladder.
Ispitivanjem u trajanju od 24 mjeseca u mužjaka štakora pokazalo se da primjena pioglitazona rezultira povećanom incidencijom hiperplastičkih promjena u mokraćnom mjehuru.
24-month mechanistic study in male rats demonstrated that administration of pioglitazone resulted in an increased incidence of hyperplastic changes in the bladder.
Mehanističko ispitivanje u trajanju od 24 mjeseca u mužjaka štakora pokazalo je da je primjena pioglitazona rezultirala povećanom incidencijom hiperplastičkih promjena u mokraćnom mjehuru.
24-month mechanistic study in male rats demonstrated that administration of pioglitazone resulted in an increased incidence of hyperplastic changes in the bladder.
Mehanističko ispitivanje u trajanju od 24 mjeseca u mužjaka štakora pokazalo je da je primjena pioglitazona rezultirala povećanom incidencijom hiperplastičnih promjena u mokraćnom mjehuru.
24-Week
tjedno
24-week arm
Skupina liječena 24 tjedna
24-weeks
24 tjedna
24.0% (p=0.055)
24,0% (p=0,055)
24.7b
57,1b
24/6 mg daily + Victrelis 800 mg
24/6 mg na dan + Victrelis 800 mg
24/6 mg)/ Elvitegravir (150 mg once daily)/ Cobicistat (150 mg once daily)
24/6 mg)/elvitegravir (150 mg jedanput na dan)/kobicistat (150 mg jedanput na dan)
240
Pakovanje
240 capsules
240 kapsule
240 mg selamectin
240 mg selamektina
240 mg twice a day.
240 mg dva puta na dan.
240 ml (120 doses)
240 ml (120 doza)
240 ml oral suspension
240 ml oralne suspenzije
2400 (3 x 20 cartridges x 40) tablets (multipack)
2400 (3 x 20 ulošci x 40) tableta (višestruko pakiranje)
2400 IU*** human von Willebrand factor** (VWF)
2400 IU*** ljudskog von Willebrandova faktora** (VWF)
240ml
doza)
240ml (120 doses)
240ml (120 doza)
24106 Kiel GERMANY
24106 Kiel NJEMAČKA
24106 Kiel Germany
24106 Kiel Njemača
24106 Kiel Germany
24106 Kiel Njemačka
24106 Kiel GERMANY
Njemačka
245 mg (as fumarate) (n = 45)
Tenofovirdizoproksil 245 mg (u obliku tenofovirdizoproksil- fumarata) (n = 45)
245 mg (as fumarate) n = 125d
245 mg (u obliku tenofovirdizoproksil- fumarata) n = 125d
245 mg (as fumarate) n = 90d
245 mg (u obliku tenofovirdizoproksil- fumarata) n = 90d
245 mg/61.25 mg modified-release hard capsule
Tvrde kapsule s prilagođenim oslobađanjem od 245 mg/61,25 mg
245 mg/61.25 mg modified-release hard capsules
Tvrde kapsule s prilagođenim oslobađanjem od 245 mg/61,25 mg
245 mg/61.25 mg, or 390 mg/97.5 mg, three times a day.
145 mg/36,25 mg, 245 mg/61,25 mg ili 390 mg/97,5 mg, tri puta dnevno.
2491 Neufeld / Leitha Austria
2491 Neufeld / Leitha Austrija
24x1 capsules + 1 inhaler.
24x1 kapsule + 1 inhalator.
25 ampoules
25 ampula
25 capsules
25 kapsula
25 capsules
25 kapsule
25 days after the first dose, administer Zycortal, as follows:
25 dana nakon prve doze, primijenite Zycortal, na sljedeći način:
25 doses
25 doze
25 doses (50 ml).
25 doza (50 ml)
25 doses for gilts and sows, 100 doses for piglets
25 doza za nazimice i krmače, 100 doza za prasad
25 doses.
25 doza
25 glass containers: powder 25 oral applicators: solvent 25 transfer adapters
25 staklenih spremnika: prašak 25 oralnih aplikatora: otapalo 25 nastavaka za prijenos
25 inhalers
25 inhalatora
25 kg to less than 30 kg
25 kg do manje od 30 kg
25 kg to less than 30 kg
od 25 kg do manje od 30 kg
25 mg BIW
25 mg 2 x tj.
25 mg capsules
Kapsule od 25 mg
25 mg daily
25 mg dnevno
25 mg dose — 1 sachet
Doza od 25 mg — 1 vrećica
25 mg Enbrel administered twice weekly is the recommended dose.
Preporučena doza Enbrela je 25 mg primijenjeno dva puta na tjednan.
25 mg film-coated tablets: polyvinyl alcohol, titanium dioxide (E171), macrogol 3350, talc, iron oxide yellow (E172), iron oxide black (E172).
25 mg filmom obložene tablete: poli(vinilni) alkohol, titanijev dioksid (E171), makrogol 3350, talk, žuti željezov oksid (E172), crni željezov oksid (E172)
25 mg hard capsules
Tvrde kapsule od 25 mg
25 mg lyophilised powder to be reconstituted with 5 ml sodium chloride 9 mg/ml (0.9%) solution for injection before administration.
25 mg liofiliziranog praška za rekonstituciju s 5 ml 9 mg/ml (0,9%) otopine natrijevog klorida za injekciju prije primjene.
25 mg of dry, lyophilised powder in an atmosphere of sulphur hexafluoride in a colourless Type I glass vial, with elastomeric closure.
25 mg suhog, liofiliziranog praška u atmosferi sumporovog heksafluorida u bezbojnoj staklenoj bočici tipa I, s elastomernim čepom.
25 mg once daily on days 1-21, every 28 days
25 mg jednom dnevno od 1. do 21. dana, svakih 28 dana
25 mg suspension for injection
25 mg suspenzija za injekciju
25 mg/kg feed) effectively prevented the development of the disease.
25 mg/kg hrane) učinkovito je spriječio razvoj bolesti.
25 mg/kg feed) was effective in controlling the clinical signs and prevented weight loss caused by the disease in untreated pigs.
25 mg/kg hrane) bio je djelotvoran u sprječavanju gubitka tjelesne težine uzrokovane bolešću u neliječenih svinja.
25 mg/ml
(staklena)
25 mg/ml
25 mg/m
25 mg/ml
butilne gume
25 mg/ml
Javlor
25 mg/ml
zatvorena sivim
25 mg: -44.6 mg/dl, add-on to metformin and a sulphonylurea: placebo -2.3 mg/dl, empagliflozin 10 mg: -35.7 mg/dl, empagliflozin 25 mg: -36.6 mg/dl).
10 mg: -46,0 mg/dl, empagliflozin 25 mg: -44,6 mg/dl, dodatak uz metformin i sulfonilureju: placebo -2,3 mg/dl, empagliflozin 10 mg: -35,7 mg/dl, empagliflozin 25 mg: -36,6 mg/dl).
25 mg: -44.6 mg/dl; add-on to metformin plus sulphonylurea, placebo: -2.3 mg/dl, empagliflozin 10 mg: -35.7 mg/dl, empagliflozin 25 mg: -36.6 mg/dl).
10 mg: -46,0 mg/dl, empagliflozin 25 mg: -44,6 mg/dl, dodatak terapiji metforminu plus sulfonilureja, placebo: -2,3 mg/dl, empagliflozin 10 mg: -35,7 mg/dl, empagliflozin 25 mg: -36,6 mg/dl).
25 mg: 14 and 28 orodispersible tablets
25 mg: 14 i 28 raspadljivih tableta za usta
25 million
18 milijuna IU/3 ml
25 million
25 milijuna IU/2,5 ml
25 million IU/2.5mL
25 milijuna IU/2,5 ml
25 ml BOTTLE LABEL
NALJEPNICA BOCE OD 25 ml
25 mm (1 inch) 23 gauge
25 mm i 23 gaugea
25 modified-release hard capsules 100 modified-release hard capsules 240 modified-release hard capsules
25 tvrdih kapsula s prilagođenim oslobađanjem 100 tvrdih kapsula s prilagođenim oslobađanjem 240 tvrdih kapsula s prilagođenim oslobađanjem
25 picogram/ml).
25 pikograma/ml).
25 pre-filled syringes and 25 sterile needles
25 štrcaljki napunjenih pojedinačnom dozom i 25 sterilnih igala
25 prefilled syringes
25 napunjenih štrcaljki
25 prefilled syringes + 25 needles
25 napunjenih štrcaljki + 25 igala
25 PREFILLED SYRINGES WITH 25 NEEDLES
25 NAPUNJENIH ŠTRCALJKI S 25 IGALA
25 PREFILLED SYRINGES WITHOUT NEEDLE
25 NAPUNJENIH ŠTRCALJKI BEZ IGLE
25 to 50 mg / day*
25 do 50 mg na dan
25 to < 32.5
25 do <32,5
25 to less than 28
od 25 do manje od 28
25 VIALS
25 BOČICA
25 vials lyophilisate
25 bočica liofilizata
25 x 1 dose
25 x 1 doza
25 x 1 dose (1 ml)
25 x 1 doza (1 ml)
25 x 2 ml ampoules
25 x 2 ml ampule
25% insulin lispro and 75% insulin lispro protamine suspension (rDNA origin)
25% inzulin lispro i 75% suspenzija inzulina lispro s protaminom (dobiveni tehnologijom
25% insulin lispro and 75% insulin lispro protamine suspension (rDNA origin)
25% inzulin lispro i 75% suspenzija inzulina lispro s protaminom (dobiveni tehnologijom rekombinantne DNK)
25% insulin lispro and 75% insulin lispro protamine suspension Subcutaneous use
25% inzulin lispro i 75% suspenzija inzulina lispro s protaminom Za potkožnu primjenu.
25%*** N/A
25%*** N/P
25, 100, and 250 mg/kg/day prior to and during mating, and continuing to Day 7 of gestation, induced reduction in the number of estrous stages per 14 days and increased the number of animals with prolonged diestrus at the highest dose tested (11 times the recommended dose on an AUC basis).
250 mg/kg/dan prije i za vrijeme parenja, i nastavkom do 7. dana gestacije, izazvala je smanjenje broja estrus faza po 14 dana, a povećala je broj životinja s duljim diestrusom pri najvišoj testiranoj dozi (11 puta preporučene doze na temelju AUC).
25, 50, 100, 200 or 300 ml of solution in a vial (Type I glass) with a stopper (bromobutyl rubber).
25, 50, 100, 200 ili 300 ml otopine u bočici (staklo tipa I) s čepom (bromobutilna guma).
25,000 units*
25 000 jedinica
25,000 – Less than 50,000
25 000 – manje od 50 000
25-desacetyl-rifampicin AUC ↓ 9%
25-dezacetil-rifampicin AUC ↓ 9
25-desacetyl-rifampicin: AUC: ↓ 9%
25-dezacetil-rifampicin: AUC: ↓ 9
25-O-desacetyl-rifabutin
25-O-desacetil-rifabutin
25-O-desacetyl-rifabutin
izloženosti 25-O-desacetil
25-O-desacetyl-rifabutin
Kombinacija INTELENCEa
25-O-desacetyl-rifabutin AUC
25-O-dezacetil-rifabutin AUC
25-O-desacetyl-rifabutin AUC ↑990%
25-O-dezacetil-rifabutin AUC ↑990
25-O-desacetyl-rifabutin AUC ↔
25-O-dezacetil-rifabutin AUC ↔
25-O-desacetyl-rifabutin AUC: ↑ 525%
25-O-desacetil-rifabutin AUC: ↑ 525
25-O-desacetyl-rifabutin Cmax
25-O-dezacetil-rifabutin Cmax
25-O-desacetyl-rifabutin Cmax ↑677%
25-O-dezacetil -rifabutin Cmax ↑677
25-O-desacetyl-rifabutin Cmin
25-O-dezacetil-rifabutin Cmin
25-O-desacetyl-rifabutin Cmin ↑1045%
25-O-dezacetil -rifabutin Cmin ↑1045
25-O-desacetyl-rifabutin Cmin ↔ 25-O-desacetyl-rifabutin Cmax ↔
25-O-dezacetil-rifabutin Cmin ↔ 25-O-dezacetil-rifabutin Cmax ↔
25-O-desacetyl-rifabutin may be expected.
osobito 5-O-dezacetil-rifabutinu.
25-O-desacetyl-rifabutin:
25-O-dezacetil-rifabutin:
25-O-desacetyl-rifabutin: AUC: ↑ 525%
25-O-dezacetil-rifabutin: AUC: ↑ 525
25-O-desacetyl-rifabutin: AUC: ↔
25-O-desacetil-rifabutin: AUC: ↔
25-O-desacetyl-rifabutin: AUC: ↔
25-O-dezacetil-rifabutin: AUC: ↔
25-O-desacetylrifabutin AUC ↑ 21
25-O-dezacetilrifabutin AUC ↑ 21
25-O-desacetylrifabutin Cmax ↑ 3.2
25-O-dezacetilrifabutin Cmax ↑ 3,2
25-O-desacetylrifabutin Cmin ↑ 7.8
25-O-dezacetilrifabutin Cmin ↑ 7,8
25-O-desacetylrifabutin: Cmax
25-O-desacetilrifabutin: Cmax 6
25-O-desacetylrifabutin: Cmax  6-fold*
25-O-desacetilrifabutin: Cmax 6
25.0 (21.7, NE)
25,0 (21,7; NP)
25.1 to 26.9
25,1 do 26,9
25.2 micrograms
25,2 mikrograma
25.7 %
Ninteda
250 capsules
250 kapsula
250 International Units/vial simoctocog alfa (100 IU/ml after reconstitution)
250 međunarodnih jedinica simoktokog alfa po bočici (100 IU/ml nakon rekonstitucije)
250 IU
250 UI
250 IU moroctocog alfa for single IV use
250 IU moroktokoga alfa za jednokratnu i.v. primjenu
250 IU octocog alfa
250 IU oktokoga alfa
250 IU octocog alfa (100 IU/ml after reconstitution).
250 IU oktokoga alfa (100 IU/ml nakon pripreme za primjenu).
250 IU* human coagulation factor VIII** (FVIII).
250 IU* ljudskog koagulacijskog faktora VIII** (FVIII)
250 IU, 500 IU, 1000 IU or 2000 IU powder in a 10 mL vial (type 1 glass) with a stopper (butyl) and a flip-off seal (aluminum) and 4 mL of solvent in a pre-filled syringe (type 1 glass) with a plunger stopper (butyl), a tip-cap (butyl) and a sterile vial adapter reconstitution device, a sterile infusion set, alcohol swabs, a plaster and a gauze pad.
250 IU, 500 IU, 1000 IU ili 2000 IU praška u bočici (staklo tipa 1) od 10 ml s čepom (butil) i prstenom (aluminij) i 4 ml otapala u napunjenoj štrcaljki (staklo tipa 1) s čepom klipa (butil), zatvaračem vrha (butil) te sterilni nastavak za bočicu za rekonstituciju, sterilni set za infuziju, vatice natopljene alkoholom, flaster i jastučić od gaze.
250 IU, 500 IU, 1000 IU, 2000 IU or 3000 IU lyophilised powder in top chamber and 4 mL of solvent in bottom chamber of the pre-filled syringe (type 1 glass) with butyl rubber plungers and closure, one plunger rod for assembly, a polypropylene vented sterile cap, a sterile infusion set, alcohol swabs, a plaster and a gauze pad.
250 IU, 500 IU, 1000 IU,2000 IU ili 3000 IU liofiliziranog praška u gornjoj komori i 4 ml otapala u donjoj komori napunjene štrcaljke (staklo tipa 1) s klipovima i zatvaračem od butilne gume, jedan potisnik klipa za sklapanje, polipropilenski propusni sterilni zatvarač, sterilni set za infuziju, vatice natopljene alkoholom, flaster i jastučić od gaze.
250 IU/vial
250 IU po bočici
250 mcg (8 m IU) per ml after reconstitution
250 µg (8 milijuna IU) po ml nakon pripreme otopine
250 mcg/0.3 ml
250 mcg/0,3 ml
250 mcg/5 ml
250 µg/5 ml
250 mg (5 sachetsa)
250 mg (5 vrećicaa)
250 mg capsule: Size number 0 capsule with a white cap (black imprint “ASK002”) and white body (black imprint “250mg”).
250 mg kapsula: kapsula veličine broj 0 s tamnonarančastom kapicom (s crnim natpisom "ASK002") i tijelom (s crnim natipsom "250 mg").
250 mg film-coated tablets: brilliant blue FCF (E133) and indigotine (E132).
250 mg filmom obložene tablete: brilliant blue FCF (E133) i indigotin (E132).
250 mg qid
Antimikotici
250 mg sachets
250 mg vrećice
250 mg single
250 mg
250 mg single
aritaprevir/ri
250 mg tablet: indigo carmine aluminium lake (E132) 500 mg tablet: iron oxide yellow (E172)
250 mg tableta: indigo carmine aluminium lake (E132) 500 mg tableta: žuti željezov oksid (E 172)
250 mg tablet: indigo carmine aluminium lake (E132), sunset yellow FCF aluminium lake (E110), quinoline yellow aluminium lake (E104)
250 mg tableta: indigo carmine aluminium lake (E132), sunset yellow FCF aluminium lake (E110), quinoline yellow aluminium lake (E104)
250 mg/dl despite optimal anti-hyperglycaemic therapy
250 mg/dl usprkos optimalnoj antidijabetičkoj terapiji
250 mg/m2/day (6.76 mg/kg/day) divided in one or two daily infusions, administered from 2 up to 5 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 800 mg/m2 (21.62 mg/kg), during the time of the entire conditioning treatment.
250 mg/m2/dan (6,76 mg/kg/dan) podijeljena u jednu ili dvije dnevne infuzije, primijenjene tijekom 2 do 5 uzastopnih dana prije autologne TKMS ovisno o kombinaciji s drugim kemoterapijskim lijekovima, bez prekoračenja ukupne maksimalne kumulativne doze od 800 mg/m2 (21,62 mg/kg), tijekom cijelog pripremnog liječenja.